Abuse potential of Soma®: The GABAA receptor as a target

Lorie A. Gonzalez, Michael B. Gatch, Michael J. Forster, Glenn H. Dillon

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Soma® (carisoprodol) is an increasingly abused, centrally-acting muscle relaxant. Despite the prevalence of carisoprodol abuse, its mechanism of action remains unclear. Its sedative effects, which contribute to its therapeutic and recreational use, are generally attributed to the actions of its primary metabolite, meprobamate, at GABAA receptors (GABAAR). Meprobamate is a controlled substance at the federal level; ironically, carisoprodol is not currently classified as such. Using behavioral and molecular pharmacological approaches, we recently demonstrated carisoprodol, itself, is capable of modulating GABAAR function in a manner similar to central nervous system depressants. Its functional similarities with this highly addictive class of drugs may contribute to the abuse potential of carisoprodol. The site of action of carisoprodol has not been identified; based on our studies, interaction with benzodiazepine or barbiturate sites is unlikely. These recent findings, when coupled with numerous reports in the literature, support the contention that the non-controlled status of carisoprodol should be reevaluated.

Original languageEnglish
Pages (from-to)180-186
Number of pages7
JournalMolecular and Cellular Pharmacology
Issue number4
StatePublished - 2009


  • Carisoprodol
  • Discrimination
  • GABA receptor
  • Meprobamate
  • Muscle relaxant
  • Substance abuse


Dive into the research topics of 'Abuse potential of Soma®: The GABAA receptor as a target'. Together they form a unique fingerprint.

Cite this